X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Aurobindo Pharma with Merck Ltd - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

AUROBINDO PHARMA vs MERCK LTD - Comparison Results

AUROBINDO PHARMA    Change

Aurobindo Pharma is one of India's top 5 pharma companies in terms of turnover, and has presence in the generic and Active Pharmaceutical Ingredients (API) segments. The company's robust product portfolio is spread across 6 product areas, including a... More

MERCK LTD 
   Change

Merck, the Indian arm of Merck KgaA (Germany), is a relatively smaller player among MNC pharma majors in the country. Merck has two business segments namely Pharmaceuticals and Chemicals. The pharmaceutical business, accounting for 68% of total sales... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    AUROBINDO PHARMA MERCK LTD AUROBINDO PHARMA/
MERCK LTD
 
P/E (TTM) x 19.1 51.0 37.4% View Chart
P/BV x 4.8 7.7 62.4% View Chart
Dividend Yield % 0.3 0.4 88.5%  

Financials

 AUROBINDO PHARMA   MERCK LTD
EQUITY SHARE DATA
    AUROBINDO PHARMA
Mar-17
MERCK LTD
Dec-16
AUROBINDO PHARMA/
MERCK LTD
5-Yr Chart
Click to enlarge
High Rs8951,060 84.4%   
Low Rs622623 99.8%   
Sales per share (Unadj.) Rs254.6632.4 40.3%  
Earnings per share (Unadj.) Rs39.345.7 85.9%  
Cash flow per share (Unadj.) Rs46.662.3 74.7%  
Dividends per share (Unadj.) Rs2.5011.00 22.7%  
Dividend yield (eoy) %0.31.3 25.2%  
Book value per share (Unadj.) Rs160.0388.8 41.1%  
Shares outstanding (eoy) m585.8816.60 3,529.4%   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x3.01.3 223.9%   
Avg P/E ratio x19.318.4 104.9%  
P/CF ratio (eoy) x16.313.5 120.6%  
Price / Book Value ratio x4.72.2 219.1%  
Dividend payout %6.424.1 26.5%   
Avg Mkt Cap Rs m444,39013,969 3,181.3%   
No. of employees `00014.01.6 883.3%   
Total wages/salary Rs m17,6781,487 1,189.0%   
Avg. sales/employee Rs Th10,667.86,631.9 160.9%   
Avg. wages/employee Rs Th1,264.3939.2 134.6%   
Avg. net profit/employee Rs Th1,645.8479.4 343.3%   
INCOME DATA
Net Sales Rs m149,15710,498 1,420.8%  
Other income Rs m1,159242 478.1%   
Total revenues Rs m150,31610,741 1,399.5%   
Gross profit Rs m34,3431,135 3,025.0%  
Depreciation Rs m4,276276 1,552.2%   
Interest Rs m6670-   
Profit before tax Rs m30,5581,102 2,772.5%   
Minority Interest Rs m500-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m7,597343 2,212.8%   
Profit after tax Rs m23,012759 3,032.3%  
Gross profit margin %23.010.8 212.9%  
Effective tax rate %24.931.1 79.8%   
Net profit margin %15.47.2 213.4%  
BALANCE SHEET DATA
Current assets Rs m92,0626,410 1,436.3%   
Current liabilities Rs m66,2238,828 750.1%   
Net working cap to sales %17.3-23.0 -75.2%  
Current ratio x1.40.7 191.5%  
Inventory Days Days10658 183.7%  
Debtors Days Days6838 176.3%  
Net fixed assets Rs m62,9191,406 4,473.7%   
Share capital Rs m586166 353.0%   
"Free" reserves Rs m93,1336,286 1,481.6%   
Net worth Rs m93,7196,455 1,452.0%   
Long term debt Rs m1,8140-   
Total assets Rs m162,4948,828 1,840.6%  
Interest coverage x46.8NM-  
Debt to equity ratio x00-  
Sales to assets ratio x0.91.2 77.2%   
Return on assets %14.68.6 169.5%  
Return on equity %24.611.8 208.8%  
Return on capital %32.717.1 191.7%  
Exports to sales %08.3 0.0%   
Imports to sales %021.0 0.0%   
Exports (fob) Rs mNA869 0.0%   
Imports (cif) Rs mNA2,209 0.0%   
Fx inflow Rs m75,838959 7,909.6%   
Fx outflow Rs m30,2242,612 1,157.1%   
Net fx Rs m45,613-1,653 -2,759.1%   
CASH FLOW
From Operations Rs m32,7861,070 3,062.9%  
From Investments Rs m-17,870-750 2,383.7%  
From Financial Activity Rs m-19,153-150 12,785.4%  
Net Cashflow Rs m-4,239171 -2,480.2%  

Share Holding

Indian Promoters % 54.1 0.0 -  
Foreign collaborators % 0.0 51.8 -  
Indian inst/Mut Fund % 8.0 18.2 43.7%  
FIIs % 27.7 1.0 2,770.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 10.2 29.1 35.1%  
Shareholders   69,601 28,591 243.4%  
Pledged promoter(s) holding % 8.6 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare AUROBINDO PHARMA With:   ABBOTT INDIA  NATCO PHARMA  BIOCON LTD  PFIZER  ALKEM LABORATORIES  

Compare AUROBINDO PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Remains Rangebound; HDFC AMC & Reliance Nippon Tumble Over 8%(12:30 pm)

Stock markets in India are trading in a range with positive bias in the afternoon session amid firm cues in the Asian markets and a recovery in rupee. Gains are largely seen in metal stocks and energy stocks.

Related Views on News

AUROBINDO PHARMA Announces Quarterly Results (1QFY19); Net Profit Down 12.0% (Quarterly Result Update)

Aug 13, 2018 | Updated on Aug 13, 2018

For the quarter ended June 2018, AUROBINDO PHARMA has posted a net profit of Rs 5 bn (down 12.0% YoY). Sales on the other hand came in at Rs 43 bn (up 15.5% YoY). Read on for a complete analysis of AUROBINDO PHARMA's quarterly results.

MERCK LTD Announces Quarterly Results (1QFY19); Net Profit Up 63.1% (Quarterly Result Update)

Aug 8, 2018 | Updated on Aug 8, 2018

For the quarter ended June 2018, MERCK LTD has posted a net profit of Rs 328 m (up 63.1% YoY). Sales on the other hand came in at Rs 2 bn (down 17.1% YoY). Read on for a complete analysis of MERCK LTD's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

In a Crisis, if Petrol Prices Hit Rs 100, This Stock Could Be a Good Buy(The 5 Minute Wrapup)

Sep 6, 2018

The rise in the crude oil price is a major reason for the fall in the market. If crude oil prices keep on rising, what will happen to stocks?

Want Bigger Returns Than You Thought Possible? This is Where You Should Look(Profit Hunter)

Sep 12, 2018

Richa has discovered the single most profitable opportunity in the market - read on to discover more...

The Secret Of Mirae Asset India Equity Fund's Increasing Popularity(Outside View)

Sep 7, 2018

The prudent investment strategies followed at the fund house has helped Mirae Asset India Equity Fund earn a tag of being a consistent performer, which is in turn gaining popularity among investors.

Hurricanes Threaten Oil Spike, but the Saudis are Selling...(Vivek Kaul's Diary)

Sep 6, 2018

Oil prices are rising and could go even more higher amid rising tensions in Middle East.

Should You Be Worried About the Rising Dollar?(Chart Of The Day)

Sep 7, 2018

While the rupee has deprecated by about 5% annually since 1990 against the dollar, the BSE Sensex has returned 14% annually in the same period.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

AUROBINDO PHARMA SHARE PRICE


Sep 19, 2018 01:21 PM

TRACK AUROBINDO PHARMA

  • Track your investment in AUROBINDO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON AUROBINDO PHARMA

AUROBINDO PHARMA - ALKEM LABORATORIES COMPARISON

COMPARE AUROBINDO PHARMA WITH

MARKET STATS